UB Paderborn / Katalog / Suche / in CDI

Long-term efficacy and safety of inebilizumab in neuromyelitis optica spectrum disorder: Analysis of aquaporin-4–immunoglobulin G–seropositive participants taking inebilizumab for ⩾4 years in the N-MOmentum trial

Multiple sclerosis, 2022-05, Vol.28 (6), p.925-932

2022

Link zum Volltext

Verfügbarkeit prüfen

Sensitivity analysis of the primary endpoint from the N-MOmentum study of inebilizumab in NMOSD

Multiple sclerosis, 2021-11, Vol.27 (13), p.2052-2061

2021

Link zum Volltext

Verfügbarkeit prüfen

Efficacy and Safety of MEDI2070, an Antibody Against Interleukin 23, Patients With Moderate to Severe Crohn's Disease: a Phase 2a Study

Gastroenterology (New York, N.Y. 1943), 2017-07, Vol.153 (1), p.77-86.e6

2017

Link zum Volltext

Verfügbarkeit prüfen

Disability Outcomes in the N-MOmentum Trial of Inebilizumab in Neuromyelitis Optica Spectrum Disorder

Neurology : neuroimmunology & neuroinflammation, 2021-05, Vol.8 (3)

2021

Link zum Volltext

Verfügbarkeit prüfen

A CD40L-targeting protein reduces autoantibodies and improves disease activity in patients with autoimmunity

Science translational medicine, 2019-04, Vol.11 (489)

2019

Link zum Volltext

Verfügbarkeit prüfen

Anifrolumab, an Anti–Interferon‐α Receptor Monoclonal Antibody, in Moderate‐to‐Severe Systemic Lupus Erythematosus

Arthritis & rheumatology (Hoboken, N.J.), 2017-02, Vol.69 (2), p.376-386

2017

Link zum Volltext

Verfügbarkeit prüfen

Depleting plasmacytoid dendritic cells reduces local type I interferon responses and disease activity in patients with cutaneous lupus

Science translational medicine, 2021-05, Vol.13 (595)

2021

Link zum Volltext

Verfügbarkeit prüfen

Sifalimumab, an anti-interferon-α monoclonal antibody, in moderate to severe systemic lupus erythematosus: a randomised, double-blind, placebo-controlled study

Annals of the rheumatic diseases, 2016-11, Vol.75 (11), p.1909-1916

2016

Link zum Volltext

Verfügbarkeit prüfen

Serum Glial Fibrillary Acidic Protein: A Neuromyelitis Optica Spectrum Disorder Biomarker

Annals of neurology, 2021-05, Vol.89 (5), p.895-910

2021

Link zum Volltext

Verfügbarkeit prüfen

A phase 1b clinical trial evaluating sifalimumab, an anti-IFN-α monoclonal antibody, shows target neutralisation of a type I IFN signature in blood of dermatomyositis and polymyositis patients

Annals of the rheumatic diseases, 2014-01, Vol.73 (1), p.256-262

2014

Link zum Volltext

Verfügbarkeit prüfen

Safety and tolerability of an anti-CD19 monoclonal antibody, MEDI-551, in subjects with systemic sclerosis: a phase I, randomized, placebo-controlled, escalating single-dose study

Arthritis research & therapy, 2016-06, Vol.18 (1), p.131-131, Article 131

2016

Link zum Volltext

Verfügbarkeit prüfen

Anifrolumab effects on rash and arthritis: impact of the type I interferon gene signature in the phase IIb MUSE study in patients with systemic lupus erythematosus

Lupus science & medicine, 2018-11, Vol.5 (1), p.e000284-e000284

2018

Link zum Volltext

Verfügbarkeit prüfen

Inebilizumab for treatment of neuromyelitis optica spectrum disorder in patients with prior rituximab use from the N-MOmentum Study

Multiple sclerosis and related disorders, 2022-01, Vol.57, p.103352-103352, Article 103352

2022

Link zum Volltext

Verfügbarkeit prüfen

Fas Gene Mutations in the Canale–Smith Syndrome, an Inherited Lymphoproliferative Disorder Associated with Autoimmunity

The New England journal of medicine, 1996-11, Vol.335 (22), p.1643-1649

1996

Link zum Volltext

Verfügbarkeit prüfen

Anifrolumab, an Anti-Interferon-[alpha] Receptor Monoclonal Antibody, in Moderate-to-Severe Systemic Lupus Erythematosus

Arthritis & rheumatology (Hoboken, N.J.), 2017-02, Vol.69 (2), p.376

2017

Link zum Volltext

Verfügbarkeit prüfen

AQP4-IgG-seronegative patient outcomes in the N-MOmentum trial of inebilizumab in neuromyelitis optica spectrum disorder

Multiple sclerosis and related disorders, 2022-01, Vol.57, p.103356-103356, Article 103356

2022

Link zum Volltext

Verfügbarkeit prüfen

Sifalimumab, an anti-interferon-[alpha] monoclonal antibody, in moderate to severe systemic lupus erythematosus: a randomised, double-blind, placebo-controlled study

Annals of the rheumatic diseases, 2016-11, Vol.75 (11), p.1909

2016

Link zum Volltext

Verfügbarkeit prüfen

830 Initial Evaluation of MEDI2070 (Specific Anti-IL-23 Antibody) in Patients With Active Crohn's Disease Who Have Failed Anti-TNF Antibody Therapy: A Randomized, Double-Blind Placebo-Controlled Phase 2A Induction Study

Gastroenterology (New York, N.Y. 1943), 2015-04, Vol.148 (4), p.S-163-S-164

2015

Link zum Volltext

Verfügbarkeit prüfen

A phase 1b clinical trial evaluating sifalimumab, an anti-IFN-[alpha] monoclonal antibody, shows target neutralisation of a type I IFN signature in blood of dermatomyositis and polymyositis patients

Annals of the rheumatic diseases, 2014-01, Vol.73 (1), p.256

2014

Link zum Volltext

Verfügbarkeit prüfen

CT-03 Anifrolumab reduces disease activity in multiple organ domains in patients with moderate to severe systemic lupus erythematosus

Lupus science & medicine, 2016-09, Vol.3 (Suppl 1), p.A39

2016

Link zum Volltext

Verfügbarkeit prüfen

Impaired T cell death and lupus-like autoimmunity in T cell-specific adapter protein-deficient mice

The Journal of experimental medicine, 2003-09, Vol.198 (5), p.809-821

2003

Link zum Volltext

Verfügbarkeit prüfen

Efficacy and Safety of Ocrelizumab in Active Proliferative Lupus Nephritis: Results From a Randomized, Double‐Blind, Phase III Study

Arthritis and rheumatism, 2013-09, Vol.65 (9), p.2368-2379

2013

Link zum Volltext

Verfügbarkeit prüfen

The Fas Protein is Expressed at High Levels on CD4+CD8+Thymocytes and Activated Mature Lymphocytes in Normal Mice but not in the Lupus-Prone Strain, MRL lpr/lpr

Proceedings of the National Academy of Sciences - PNAS, 1993-11, Vol.90 (21), p.10340-10344

1993

Link zum Volltext

Verfügbarkeit prüfen

The defect in Fas mRNA expression in MRL/lpr mice is associated with insertion of the retrotransposon, ETn

The Journal of experimental medicine, 1993-08, Vol.178 (2), p.723-730

1993

Link zum Volltext

Verfügbarkeit prüfen

Safety and pharmacodynamics of rontalizumab in patients with systemic lupus erythematosus: Results of a phase I, placebo-controlled, double-blind, dose-escalation study

Arthritis and rheumatism, 2012-11, Vol.64 (11), p.3666-3676

2012

Link zum Volltext

Verfügbarkeit prüfen

Menü

Weitere Dienste

Einstellungen

Long-term efficacy and safety of inebilizumab in neuromyelitis optica spectrum disorder: Analysis of aquaporin-4–immunoglobulin G–seropositive participants taking inebilizumab for ⩾4 years in the N-MOmentum trial

Sensitivity analysis of the primary endpoint from the N-MOmentum study of inebilizumab in NMOSD

Efficacy and Safety of MEDI2070, an Antibody Against Interleukin 23, Patients With Moderate to Severe Crohn's Disease: a Phase 2a Study

Disability Outcomes in the N-MOmentum Trial of Inebilizumab in Neuromyelitis Optica Spectrum Disorder

A CD40L-targeting protein reduces autoantibodies and improves disease activity in patients with autoimmunity

Anifrolumab, an Anti–Interferon‐α Receptor Monoclonal Antibody, in Moderate‐to‐Severe Systemic Lupus Erythematosus

Depleting plasmacytoid dendritic cells reduces local type I interferon responses and disease activity in patients with cutaneous lupus

Sifalimumab, an anti-interferon-α monoclonal antibody, in moderate to severe systemic lupus erythematosus: a randomised, double-blind, placebo-controlled study

Serum Glial Fibrillary Acidic Protein: A Neuromyelitis Optica Spectrum Disorder Biomarker

A phase 1b clinical trial evaluating sifalimumab, an anti-IFN-α monoclonal antibody, shows target neutralisation of a type I IFN signature in blood of dermatomyositis and polymyositis patients

Safety and tolerability of an anti-CD19 monoclonal antibody, MEDI-551, in subjects with systemic sclerosis: a phase I, randomized, placebo-controlled, escalating single-dose study

Anifrolumab effects on rash and arthritis: impact of the type I interferon gene signature in the phase IIb MUSE study in patients with systemic lupus erythematosus

Inebilizumab for treatment of neuromyelitis optica spectrum disorder in patients with prior rituximab use from the N-MOmentum Study

Fas Gene Mutations in the Canale–Smith Syndrome, an Inherited Lymphoproliferative Disorder Associated with Autoimmunity

Anifrolumab, an Anti-Interferon-[alpha] Receptor Monoclonal Antibody, in Moderate-to-Severe Systemic Lupus Erythematosus

AQP4-IgG-seronegative patient outcomes in the N-MOmentum trial of inebilizumab in neuromyelitis optica spectrum disorder

Sifalimumab, an anti-interferon-[alpha] monoclonal antibody, in moderate to severe systemic lupus erythematosus: a randomised, double-blind, placebo-controlled study

830 Initial Evaluation of MEDI2070 (Specific Anti-IL-23 Antibody) in Patients With Active Crohn's Disease Who Have Failed Anti-TNF Antibody Therapy: A Randomized, Double-Blind Placebo-Controlled Phase 2A Induction Study

A phase 1b clinical trial evaluating sifalimumab, an anti-IFN-[alpha] monoclonal antibody, shows target neutralisation of a type I IFN signature in blood of dermatomyositis and polymyositis patients

CT-03 Anifrolumab reduces disease activity in multiple organ domains in patients with moderate to severe systemic lupus erythematosus

Impaired T cell death and lupus-like autoimmunity in T cell-specific adapter protein-deficient mice

Efficacy and Safety of Ocrelizumab in Active Proliferative Lupus Nephritis: Results From a Randomized, Double‐Blind, Phase III Study

The Fas Protein is Expressed at High Levels on CD4+CD8+Thymocytes and Activated Mature Lymphocytes in Normal Mice but not in the Lupus-Prone Strain, MRL lpr/lpr

The defect in Fas mRNA expression in MRL/lpr mice is associated with insertion of the retrotransposon, ETn

Safety and pharmacodynamics of rontalizumab in patients with systemic lupus erythematosus: Results of a phase I, placebo-controlled, double-blind, dose-escalation study

Suchergebnisse filtern